Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesComparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort studyComparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related TolerabilityThe clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohortDerivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 yearDetermining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.The practitioner proposes a treatment change and the patient declines: what to do next?Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.Simultaneous Treatment with Subcutaneous Injection of Golimumab and Intra-articular Injection of Triamcinolone Acetonide (K-Method) in Patients with Rheumatoid Arthritis Undergoing Switching of Biologics: Retrospective Case-Control Study.Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point.Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial.Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
P2860
Q26778600-BF2D82AF-C585-4C81-BA79-74B449BC94F2Q28542423-37C61568-4ABA-4AA2-B65E-8B32EA33250DQ28550952-02E90A26-A168-4719-A964-D375D7AD8B03Q31151686-629B5FE4-05DD-4F0B-98F8-77405E6AFC29Q34264302-1CB82ADD-78FE-4A77-A83D-8F50BF3481F8Q35840753-354FE688-2C04-42A7-B10B-23411BC4EDB1Q35899269-F39B5918-3848-4E4D-BB90-2C028900A638Q36087222-CB129C9A-A9FE-4997-A6CE-0BC01EDE0DD0Q36889224-CB587C15-A79E-4E15-90A7-431E82288954Q37143744-E2303BD7-E55E-4C0E-B49E-A1B40D7682ABQ38648469-B050BE74-A09A-44F2-B36E-1985E068BAA5Q38921982-DDAE9217-0501-4670-9124-DADCDEBB188EQ39883836-51246D25-9417-4800-89B5-1CD0B0FF352BQ40314992-D4E7D61A-F207-4D64-88E6-A9D39C3ED47FQ40484774-FC8ABE2E-4553-45A7-AF10-3E36CADF774EQ44414554-7753E1E5-3E8E-47A5-89EC-E54030A9BF3DQ45805620-433B9B36-DCC1-4FB9-B8EE-1C559BCC21F8Q50591145-8AB35681-013F-41FD-A68A-69756C172BEEQ50919081-87F20142-AF90-41F4-A65F-9671FE953F0D
P2860
Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Thresholds in disease activity ...... ence from a large U.S. cohort.
@ast
Thresholds in disease activity ...... ence from a large U.S. cohort.
@en
type
label
Thresholds in disease activity ...... ence from a large U.S. cohort.
@ast
Thresholds in disease activity ...... ence from a large U.S. cohort.
@en
prefLabel
Thresholds in disease activity ...... ence from a large U.S. cohort.
@ast
Thresholds in disease activity ...... ence from a large U.S. cohort.
@en
P2093
P2860
P356
P1476
Thresholds in disease activity ...... ence from a large U.S. cohort.
@en
P2093
George Reed
Jeffrey D Greenberg
Jeffrey R Curtis
Joel Kremer
Scott Baumgartner
P2860
P304
P356
10.1002/ACR.20643
P577
2011-12-01T00:00:00Z